Predict your next investment

Flash Therapeutics company logo
Corporation
HEALTHCARE | Biotechnology
flashtherapeutics.com

See what CB Insights has to offer

Stage

Seed VC | Alive

Total Raised

$3.9M

Last Raised

$3.9M | 3 yrs ago

About Flash Therapeutics

Flash Therapeutics, formed by the merger of FlashCell and Vectalys, is developing gene and cell-based therapies, leveraging its proprietary lentiviral platform and bioproduction technologies. The company is built around the Vectalys lentiviral platform, which includes its patented non-integrative LentiFlash technology, and integrative lentiviral vectors.

Flash Therapeutics Headquarter Location

Canal Biotech II 3 rue des satellites

Toulouse, 31400,

France

+33 5 61 28 70 75

Latest Flash Therapeutics News

Global Bacterial and Plasmid Vectors Market Report 2020-2030 Featuring Sigma-Aldrich, ATUM, QIAGEN, Promega, Thermo Fisher Scien...

Jan 13, 2021

News provided by Share this article Major players in the bacterial and plasmid vectors market are Sigma-Aldrich Inc., ATUM, QIAGEN, Promega Corporation, Thermo Fisher Scientific, Inc., GenScript Biotech Corporation, Takara Bio Inc., IBA GmbH, Bio-Rad Laboratories and New England Biolabs. The global bacterial and plasmid vectors market is expected to decline from $0.36 billion in 2019 to $0.34 billion in 2020 at a compound annual growth rate (CAGR) of -7.62%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $0.52 billion in 2023 at a CAGR of 15.48%. The bacterial and plasmid vectors market consists of sales of bacterial and plasmid vectors and related services by entities (organizations, sole traders and partnerships) that develop bacterial and plasmid vectors for biotechnological applications. Bacterial vectors are DNA molecules that are the basic tool of genetic engineering and are used to introduce foreign genetic material into a host to replicate and amplify the foreign DNA sequences as a recombinant molecule. The vectors are used for introducing a definite gene into the target cell and command the cell's mechanism for protein synthesis to produce the protein encoded by the gene. These are used for the production of protein in biotechnology applications. North America was the largest region in the bacterial and plasmid vectors market in 2019. Asia-Pacific is expected to be the fastest-growing region in the forecast period. In May 2018, Vectalys, a France-based company engaged in manufacturing and commercializing lentiviral vectors for gene delivery, and FlashCell, a company engineering non-integrating lentiviral delivered RNA therapeutics, announced their merger to create a new gene therapy company - Flash Therapeutics. Flash Therapeutics is expected to collaborate on the two complementary businesses of Vectalys and FlashCell and combine the emergence of cell and gene therapies as major new therapeutic modalities for the treatment of incurable diseases. Flash Therapeutics is a new gene and cell therapy company based in Occitanie, France engaged in developing gene and cell-based therapies by leveraging its bioproduction technologies and lentiviral platform. The high cost of gene therapy is expected to limit the growth of the bacterial and plasmid vectors market during the forecast period. The cost of gene therapy treatments approved by the Food and Drug Administration is between $0.3 million and $2.1 million. Moreover, the cost of Luxturna gene therapy for certain inherited retinal diseases (IRDs) is $0.4 million per eye and LentiGlobin, a gene therapy by Bluebird Bio designed to increase the levels of hemoglobin, costs around $2.1 million. Stringent government regulations, long approval processes, and high production costs are the major factors leading to the high cost of gene therapy. Thus, the high cost of gene therapy is expected to hinder the growth of the bacterial and plasmid vectors market in the near future. The focus areas for many companies in the bacterial and plasmid vectors market has shifted to mergers and acquisitions to enhance production capabilities. Large prime manufactures are forming joint ventures or buying small or midsized companies to acquire new capabilities or to gain access to new markets. The increasing prevalence of cancer and infectious diseases is anticipated to boost the demand for the bacterial and plasmid vectors market over the coming years. Bacterial vectors are used for the delivery of recombinant proteins into target cells for the treatment of cancer and various infectious diseases. According to the World Health Organization (WHO), cancer is the second leading cause of death worldwide, responsible for an estimated 9.6 million deaths in 2018. The growing prevalence of cancer and various infectious diseases and the increasing demand for bacterial and plasmid vectors for gene therapy are projected to propel the market revenues for the bacterial and plasmid vectors market. Key Topics Covered: 3. Bacterial and Plasmid Vectors Market Size and Growth 3.1. Global Bacterial and Plasmid Vectors Historic Market, 2015 - 2019, $ Billion 3.1.1. Drivers of the Market 3.1.2. Restraints on the Market 3.2. Global Bacterial and Plasmid Vectors Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion 3.2.1. Drivers of the Market 3.2.2. Restraints on the Market 4. Bacterial and Plasmid Vectors Market Segmentation 4.1. Global Bacterial and Plasmid Vectors Market, Segmentation by Host Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion E.Coli Expression Vectors Other Bacterial Expression Vectors 4.2. Global Bacterial and Plasmid Vectors Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion Genetics

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Flash Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Flash Therapeutics is included in 3 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

B

Biopharmaceuticals

5,726 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

R

Regenerative Medicine

1,708 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Flash Therapeutics Patents

Flash Therapeutics has filed 2 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Transcription factors
  • Virology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/12/2017

12/22/2020

Molecular biology, Genetics, Virology, Biotechnology, Transcription factors

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

5/12/2017

00/00/0000

Grant Date

12/22/2020

00/00/0000

Title

Subscribe to see more

Related Topics

Molecular biology, Genetics, Virology, Biotechnology, Transcription factors

Subscribe to see more

Status

Grant

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.